市場調査レポート

商品コード

1472282

抗体生産市場：製品別、工程別、エンドユーザー別：世界の機会分析と産業予測、2023～2032年

Antibody Production Market By Product, By Process, By End User : Global Opportunity Analysis and Industry Forecast, 2023-2032

出版日: 2024年03月01日
発行: Allied Market Research
ページ情報: 英文 276 Pages
納期: 2～3営業日

価格

PDF (Business License)

USD 5,730 836,236円

レポートPDFを1名がご利用いただけるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。印刷は5回まで可能です。 2名以上でご利用の場合、追加料金を支払う事によりユーザーを最大５名まで追加する事が可能です。

PDF (Enterprise User License) & Excel (Data Pack) & Free Update

USD 9,600 1,401,024円

レポートPDFとExcel定量データをひとつの企業、及びその子会社でご利用頂けるライセンスです。ライセンスを付与されたPCでのみレポートPDFとExcelの保存、表示、利用が可能です。PDFとExcel内のテキスト等のコピー＆ペーストは可能です。PDFとExcelの印刷回数の制限はありません。印刷したレポートの利用は企業、及びその子会社内にて共有可能です。無料でレポートのアップデートがご利用いただけます。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=145.94円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

抗体生産市場は2022年に123億米ドルと評価され、2023～2032年のCAGRは9.1%を記録し、2032年には294億米ドルに達すると予測されています。

抗体生産とは、B細胞と呼ばれる免疫系の特殊な細胞が、細菌、ウイルス、その他の病原体などの異物の存在に反応して抗体を生産する工程を指します。抗体は、免疫グロブリンとしても知られるY字型のタンパク質で、病原体の表面に存在する特異的な分子である抗原を特異的に認識して結合します。

抗体生産の工程は、B細胞がその特異的レセプターと一致する抗原に遭遇することから始まる。この出会いがB細胞の活性化と増殖の引き金となり、クローンとして知られる同一のB細胞が大量に生産されます。活性化されたB細胞はその後、抗体生産工場である形質細胞に分化します。血漿細胞は大量の抗体を血流やその他の体液中に分泌し、そこで病原体と結合して中和したり、他の免疫細胞による破壊の目印となったりします。

抗体製造市場の成長を促す要因としては、標的療法を必要とする慢性疾患の増加、生産効率と拡大性を高めるバイオテクノロジーの進歩、治療と研究用途におけるモノクローナル抗体の需要増加、抗体ベースの研究開発を促進する政府の支援策が挙げられます。さらに、バイオ医薬品業界は、研究開発への投資の増加や生物製剤ベースの治療法の採用増加により、急速な成長を遂げています。抗体はバイオ医薬品の大部分を占めており、抗体製造技術やサービスの需要を牽引しています。

さらに、バイオテクノロジー研究開発の促進を目的とした政府の取り組みや、バイオ医薬品企業や学術機関への資金援助が、抗体作製市場の革新と成長を促進しています。官民パートナーシップや助成金制度も、抗体関連の研究や商業化の拡大に貢献しています。例えば、2023年には、抗体生産に関する政府の取り組みとして、HIV感染から身を守るための広範中和HIV抗体など、免疫応答の確立と維持のメカニズムを明らかにするための研究を支援する米国国立衛生研究所（NIH）が予定されています。このように、抗体の研究と商業化のための政府のイニシアチブの増加は、市場の成長をさらに促進します。さらに、モノクローナル抗体（mAbs）は、その高い特異性と有効性により、様々な治療セグメントで広く受け入れられています。承認されたモノクローナル抗体医薬品の数の増加と、腫瘍学、免疫学、その他のセグメントでの用途の拡大が、抗体製造と試薬の需要を牽引しています。

しかし、抗体の開発と生産に関連する高コストは、抗体生産市場の成長に大きな抑制要因となっています。抗体の開発には、抗原の選択、ハイブリドーマやファージディスプレイライブラリーの作製、抗体のスクリーニング、最適化など、一連の複雑かつ資源集約的な工程が必要です。これらの工程には、専門的な知識、高度な機器、広範な実験室リソースが必要であり、開発コストを押し上げています。さらに、治療用抗体の生産には、大規模な細胞培養、精製、製剤化、品質管理の工程が含まれ、これらすべてが生産コストの高騰につながり、市場の成長を抑制する可能性があります。一方、バイオ医薬品産業の成長と研究開発への投資の増加は、市場成長の機会となっています。

抗体作製市場は、製品、工程、エンドユーザー、地域によって区分されます。製品別では、市場は機器と消耗品に二分されます。機器セグメントはさらにバイオリアクター、クロマトグラフィーシステム、濾過システムに分類されます。工程別では、市場は上流工程と下流工程に分けられます。エンドユーザー別では、製薬・バイオテクノロジー企業、CRO・CDMO、その他に分類されます。

利害関係者にとっての主要メリット

当レポートでは、2022～2032年までの抗体作製市場分析の市場セグメント、現在の動向、推定・動向、力学を定量的に分析し、一般的な抗体作製市場の機会を特定します。
市場促進要因、市場抑制要因、市場機会に関連する情報とともに市場調査を記載しています。
ポーターのファイブフォース分析では、利害関係者が利益重視のビジネス決定を下し、サプライヤーとバイヤーのネットワークを強化できるよう、バイヤーとサプライヤーの潜在力を明らかにします。
抗体作製市場のセグメンテーションを詳細に分析することで、市場機会を見極めることができます。
各地域の主要国は、世界市場への収益貢献度に応じてマッピングされています。
市場参入企業のポジショニングはベンチマーキングを容易にし、市場参入企業の現在のポジションを明確に理解することができます。
本レポートには、地域別と世界の抗体作製市場動向、主要企業、市場セグメント、用途セグメント、市場成長戦略の分析が含まれています。

本レポートのカスタマイズが可能です（別途費用と期間がかかりますので、詳細は営業担当者にお問い合わせください）。

規制ガイドライン
顧客の関心に応じた企業プロファイルの追加
国別または地域別の追加分析-市場規模と予測
企業プロファイルの拡大リスト
過去の市場データ
主要参入企業の詳細（所在地、連絡先、サプライヤー/ベンダーネットワークなどを含む、エクセル形式）

概要
北米
- 米国
- カナダ
- メキシコ
欧州
- ドイツ
- フランス
- 英国
- イタリア
- スペイン
- その他
アジア太平洋
- 日本
- 中国
- インド
- オーストラリア
- 韓国
- その他
ラテンアメリカ
- ブラジル
- コロンビア
- アルゼンチン
- その他のラテンアメリカ
中東・アフリカ
- Gcc
- 南アフリカ
- 北アフリカ
- その他

第8章競争情勢

イントロダクション
主要成功戦略
主要10社の製品マッピング
競合ダッシュボード
競合ヒートマップ
主要企業のポジショニング、2022年

第9章企業プロファイル

Thermo Fisher Scientific Inc.
Sartorius AG
Cellabcdmo
Agilent Technologies, Inc.
Genetix Biotech Asia Pvt. Ltd.
Cell Culture Company
Bio-Rad Laboratories, Inc.
TECNIC
Merck KGaA
Danaher Corporation

図表

LIST OF TABLES

TABLE 01. GLOBAL ANTIBODY PRODUCTION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 02. ANTIBODY PRODUCTION MARKET FOR INSTRUMENTS, BY REGION, 2022-2032 ($MILLION)
TABLE 03. GLOBAL INSTRUMENTS ANTIBODY PRODUCTION MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 04. ANTIBODY PRODUCTION MARKET FOR CONSUMABLES, BY REGION, 2022-2032 ($MILLION)
TABLE 05. GLOBAL ANTIBODY PRODUCTION MARKET, BY PROCESS, 2022-2032 ($MILLION)
TABLE 06. ANTIBODY PRODUCTION MARKET FOR UPSTREAM PROCESSING, BY REGION, 2022-2032 ($MILLION)
TABLE 07. ANTIBODY PRODUCTION MARKET FOR DOWNSTREAM PROCESSING, BY REGION, 2022-2032 ($MILLION)
TABLE 08. GLOBAL ANTIBODY PRODUCTION MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 09. ANTIBODY PRODUCTION MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY REGION, 2022-2032 ($MILLION)
TABLE 10. ANTIBODY PRODUCTION MARKET FOR CROS AND CDMOS, BY REGION, 2022-2032 ($MILLION)
TABLE 11. ANTIBODY PRODUCTION MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
TABLE 12. ANTIBODY PRODUCTION MARKET, BY REGION, 2022-2032 ($MILLION)
TABLE 13. NORTH AMERICA ANTIBODY PRODUCTION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 14. NORTH AMERICA ANTIBODY PRODUCTION MARKET, BY PROCESS, 2022-2032 ($MILLION)
TABLE 15. NORTH AMERICA ANTIBODY PRODUCTION MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 16. NORTH AMERICA ANTIBODY PRODUCTION MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 17. U.S. ANTIBODY PRODUCTION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 18. U.S. ANTIBODY PRODUCTION MARKET, BY PROCESS, 2022-2032 ($MILLION)
TABLE 19. U.S. ANTIBODY PRODUCTION MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 20. CANADA ANTIBODY PRODUCTION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 21. CANADA ANTIBODY PRODUCTION MARKET, BY PROCESS, 2022-2032 ($MILLION)
TABLE 22. CANADA ANTIBODY PRODUCTION MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 23. MEXICO ANTIBODY PRODUCTION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 24. MEXICO ANTIBODY PRODUCTION MARKET, BY PROCESS, 2022-2032 ($MILLION)
TABLE 25. MEXICO ANTIBODY PRODUCTION MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 26. EUROPE ANTIBODY PRODUCTION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 27. EUROPE ANTIBODY PRODUCTION MARKET, BY PROCESS, 2022-2032 ($MILLION)
TABLE 28. EUROPE ANTIBODY PRODUCTION MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 29. EUROPE ANTIBODY PRODUCTION MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 30. GERMANY ANTIBODY PRODUCTION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 31. GERMANY ANTIBODY PRODUCTION MARKET, BY PROCESS, 2022-2032 ($MILLION)
TABLE 32. GERMANY ANTIBODY PRODUCTION MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 33. FRANCE ANTIBODY PRODUCTION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 34. FRANCE ANTIBODY PRODUCTION MARKET, BY PROCESS, 2022-2032 ($MILLION)
TABLE 35. FRANCE ANTIBODY PRODUCTION MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 36. UK ANTIBODY PRODUCTION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 37. UK ANTIBODY PRODUCTION MARKET, BY PROCESS, 2022-2032 ($MILLION)
TABLE 38. UK ANTIBODY PRODUCTION MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 39. ITALY ANTIBODY PRODUCTION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 40. ITALY ANTIBODY PRODUCTION MARKET, BY PROCESS, 2022-2032 ($MILLION)
TABLE 41. ITALY ANTIBODY PRODUCTION MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 42. SPAIN ANTIBODY PRODUCTION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 43. SPAIN ANTIBODY PRODUCTION MARKET, BY PROCESS, 2022-2032 ($MILLION)
TABLE 44. SPAIN ANTIBODY PRODUCTION MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 45. REST OF EUROPE ANTIBODY PRODUCTION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 46. REST OF EUROPE ANTIBODY PRODUCTION MARKET, BY PROCESS, 2022-2032 ($MILLION)
TABLE 47. REST OF EUROPE ANTIBODY PRODUCTION MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 48. ASIA-PACIFIC ANTIBODY PRODUCTION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 49. ASIA-PACIFIC ANTIBODY PRODUCTION MARKET, BY PROCESS, 2022-2032 ($MILLION)
TABLE 50. ASIA-PACIFIC ANTIBODY PRODUCTION MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 51. ASIA-PACIFIC ANTIBODY PRODUCTION MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 52. JAPAN ANTIBODY PRODUCTION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 53. JAPAN ANTIBODY PRODUCTION MARKET, BY PROCESS, 2022-2032 ($MILLION)
TABLE 54. JAPAN ANTIBODY PRODUCTION MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 55. CHINA ANTIBODY PRODUCTION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 56. CHINA ANTIBODY PRODUCTION MARKET, BY PROCESS, 2022-2032 ($MILLION)
TABLE 57. CHINA ANTIBODY PRODUCTION MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 58. INDIA ANTIBODY PRODUCTION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 59. INDIA ANTIBODY PRODUCTION MARKET, BY PROCESS, 2022-2032 ($MILLION)
TABLE 60. INDIA ANTIBODY PRODUCTION MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 61. AUSTRALIA ANTIBODY PRODUCTION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 62. AUSTRALIA ANTIBODY PRODUCTION MARKET, BY PROCESS, 2022-2032 ($MILLION)
TABLE 63. AUSTRALIA ANTIBODY PRODUCTION MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 64. SOUTH KOREA ANTIBODY PRODUCTION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 65. SOUTH KOREA ANTIBODY PRODUCTION MARKET, BY PROCESS, 2022-2032 ($MILLION)
TABLE 66. SOUTH KOREA ANTIBODY PRODUCTION MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 67. REST OF ASIA-PACIFIC ANTIBODY PRODUCTION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 68. REST OF ASIA-PACIFIC ANTIBODY PRODUCTION MARKET, BY PROCESS, 2022-2032 ($MILLION)
TABLE 69. REST OF ASIA-PACIFIC ANTIBODY PRODUCTION MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 70. LATIN AMERICA ANTIBODY PRODUCTION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 71. LATIN AMERICA ANTIBODY PRODUCTION MARKET, BY PROCESS, 2022-2032 ($MILLION)
TABLE 72. LATIN AMERICA ANTIBODY PRODUCTION MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 73. LATIN AMERICA ANTIBODY PRODUCTION MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 74. BRAZIL ANTIBODY PRODUCTION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 75. BRAZIL ANTIBODY PRODUCTION MARKET, BY PROCESS, 2022-2032 ($MILLION)
TABLE 76. BRAZIL ANTIBODY PRODUCTION MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 77. COLOMBIA ANTIBODY PRODUCTION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 78. COLOMBIA ANTIBODY PRODUCTION MARKET, BY PROCESS, 2022-2032 ($MILLION)
TABLE 79. COLOMBIA ANTIBODY PRODUCTION MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 80. ARGENTINA ANTIBODY PRODUCTION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 81. ARGENTINA ANTIBODY PRODUCTION MARKET, BY PROCESS, 2022-2032 ($MILLION)
TABLE 82. ARGENTINA ANTIBODY PRODUCTION MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 83. REST OF LA ANTIBODY PRODUCTION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 84. REST OF LA ANTIBODY PRODUCTION MARKET, BY PROCESS, 2022-2032 ($MILLION)
TABLE 85. REST OF LA ANTIBODY PRODUCTION MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 86. MIDDLE EAST AND AFRICA ANTIBODY PRODUCTION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 87. MIDDLE EAST AND AFRICA ANTIBODY PRODUCTION MARKET, BY PROCESS, 2022-2032 ($MILLION)
TABLE 88. MIDDLE EAST AND AFRICA ANTIBODY PRODUCTION MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 89. MIDDLE EAST AND AFRICA ANTIBODY PRODUCTION MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 90. GCC ANTIBODY PRODUCTION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 91. GCC ANTIBODY PRODUCTION MARKET, BY PROCESS, 2022-2032 ($MILLION)
TABLE 92. GCC ANTIBODY PRODUCTION MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 93. SOUTH AFRICA ANTIBODY PRODUCTION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 94. SOUTH AFRICA ANTIBODY PRODUCTION MARKET, BY PROCESS, 2022-2032 ($MILLION)
TABLE 95. SOUTH AFRICA ANTIBODY PRODUCTION MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 96. NORTH AFRICA ANTIBODY PRODUCTION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 97. NORTH AFRICA ANTIBODY PRODUCTION MARKET, BY PROCESS, 2022-2032 ($MILLION)
TABLE 98. NORTH AFRICA ANTIBODY PRODUCTION MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 99. REST OF MEA ANTIBODY PRODUCTION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 100. REST OF MEA ANTIBODY PRODUCTION MARKET, BY PROCESS, 2022-2032 ($MILLION)
TABLE 101. REST OF MEA ANTIBODY PRODUCTION MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 102. THERMO FISHER SCIENTIFIC INC.: KEY EXECUTIVES
TABLE 103. THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT
TABLE 104. THERMO FISHER SCIENTIFIC INC.: PRODUCT SEGMENTS
TABLE 105. THERMO FISHER SCIENTIFIC INC.: SERVICE SEGMENTS
TABLE 106. THERMO FISHER SCIENTIFIC INC.: PRODUCT PORTFOLIO
TABLE 107. THERMO FISHER SCIENTIFIC INC.: KEY STRATERGIES
TABLE 108. SARTORIUS AG: KEY EXECUTIVES
TABLE 109. SARTORIUS AG: COMPANY SNAPSHOT
TABLE 110. SARTORIUS AG: PRODUCT SEGMENTS
TABLE 111. SARTORIUS AG: SERVICE SEGMENTS
TABLE 112. SARTORIUS AG: PRODUCT PORTFOLIO
TABLE 113. SARTORIUS AG: KEY STRATERGIES
TABLE 114. CELLABCDMO: KEY EXECUTIVES
TABLE 115. CELLABCDMO: COMPANY SNAPSHOT
TABLE 116. CELLABCDMO: PRODUCT SEGMENTS
TABLE 117. CELLABCDMO: SERVICE SEGMENTS
TABLE 118. CELLABCDMO: PRODUCT PORTFOLIO
TABLE 119. CELLABCDMO: KEY STRATERGIES
TABLE 120. AGILENT TECHNOLOGIES, INC.: KEY EXECUTIVES
TABLE 121. AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT
TABLE 122. AGILENT TECHNOLOGIES, INC.: PRODUCT SEGMENTS
TABLE 123. AGILENT TECHNOLOGIES, INC.: SERVICE SEGMENTS
TABLE 124. AGILENT TECHNOLOGIES, INC.: PRODUCT PORTFOLIO
TABLE 125. AGILENT TECHNOLOGIES, INC.: KEY STRATERGIES
TABLE 126. GENETIX BIOTECH ASIA PVT. LTD.: KEY EXECUTIVES
TABLE 127. GENETIX BIOTECH ASIA PVT. LTD.: COMPANY SNAPSHOT
TABLE 128. GENETIX BIOTECH ASIA PVT. LTD.: PRODUCT SEGMENTS
TABLE 129. GENETIX BIOTECH ASIA PVT. LTD.: SERVICE SEGMENTS
TABLE 130. GENETIX BIOTECH ASIA PVT. LTD.: PRODUCT PORTFOLIO
TABLE 131. GENETIX BIOTECH ASIA PVT. LTD.: KEY STRATERGIES
TABLE 132. CELL CULTURE COMPANY: KEY EXECUTIVES
TABLE 133. CELL CULTURE COMPANY: COMPANY SNAPSHOT
TABLE 134. CELL CULTURE COMPANY: PRODUCT SEGMENTS
TABLE 135. CELL CULTURE COMPANY: SERVICE SEGMENTS
TABLE 136. CELL CULTURE COMPANY: PRODUCT PORTFOLIO
TABLE 137. CELL CULTURE COMPANY: KEY STRATERGIES
TABLE 138. BIO-RAD LABORATORIES, INC. : KEY EXECUTIVES
TABLE 139. BIO-RAD LABORATORIES, INC. : COMPANY SNAPSHOT
TABLE 140. BIO-RAD LABORATORIES, INC. : PRODUCT SEGMENTS
TABLE 141. BIO-RAD LABORATORIES, INC. : SERVICE SEGMENTS
TABLE 142. BIO-RAD LABORATORIES, INC. : PRODUCT PORTFOLIO
TABLE 143. BIO-RAD LABORATORIES, INC. : KEY STRATERGIES
TABLE 144. TECNIC: KEY EXECUTIVES
TABLE 145. TECNIC: COMPANY SNAPSHOT
TABLE 146. TECNIC: PRODUCT SEGMENTS
TABLE 147. TECNIC: SERVICE SEGMENTS
TABLE 148. TECNIC: PRODUCT PORTFOLIO
TABLE 149. TECNIC: KEY STRATERGIES
TABLE 150. MERCK KGAA: KEY EXECUTIVES
TABLE 151. MERCK KGAA: COMPANY SNAPSHOT
TABLE 152. MERCK KGAA: PRODUCT SEGMENTS
TABLE 153. MERCK KGAA: SERVICE SEGMENTS
TABLE 154. MERCK KGAA: PRODUCT PORTFOLIO
TABLE 155. MERCK KGAA: KEY STRATERGIES
TABLE 156. DANAHER CORPORATION: KEY EXECUTIVES
TABLE 157. DANAHER CORPORATION: COMPANY SNAPSHOT
TABLE 158. DANAHER CORPORATION: PRODUCT SEGMENTS
TABLE 159. DANAHER CORPORATION: SERVICE SEGMENTS
TABLE 160. DANAHER CORPORATION: PRODUCT PORTFOLIO
TABLE 161. DANAHER CORPORATION: KEY STRATERGIES

LIST OF FIGURES

FIGURE 01. ANTIBODY PRODUCTION MARKET, 2022-2032
FIGURE 02. SEGMENTATION OF ANTIBODY PRODUCTION MARKET,2022-2032
FIGURE 03. TOP IMPACTING FACTORS IN ANTIBODY PRODUCTION MARKET
FIGURE 04. TOP INVESTMENT POCKETS IN ANTIBODY PRODUCTION MARKET (2023-2032)
FIGURE 05. BARGAINING POWER OF SUPPLIERS
FIGURE 06. BARGAINING POWER OF BUYERS
FIGURE 07. THREAT OF SUBSTITUTION
FIGURE 08. THREAT OF SUBSTITUTION
FIGURE 09. COMPETITIVE RIVALRY
FIGURE 10. GLOBAL ANTIBODY PRODUCTION MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
FIGURE 11. ANTIBODY PRODUCTION MARKET, BY PRODUCT, 2022 AND 2032(%)
FIGURE 12. COMPARATIVE SHARE ANALYSIS OF ANTIBODY PRODUCTION MARKET FOR INSTRUMENTS, BY COUNTRY 2022 AND 2032(%)
FIGURE 13. COMPARATIVE SHARE ANALYSIS OF ANTIBODY PRODUCTION MARKET FOR CONSUMABLES, BY COUNTRY 2022 AND 2032(%)
FIGURE 14. ANTIBODY PRODUCTION MARKET, BY PROCESS, 2022 AND 2032(%)
FIGURE 15. COMPARATIVE SHARE ANALYSIS OF ANTIBODY PRODUCTION MARKET FOR UPSTREAM PROCESSING, BY COUNTRY 2022 AND 2032(%)
FIGURE 16. COMPARATIVE SHARE ANALYSIS OF ANTIBODY PRODUCTION MARKET FOR DOWNSTREAM PROCESSING, BY COUNTRY 2022 AND 2032(%)
FIGURE 17. ANTIBODY PRODUCTION MARKET, BY END USER, 2022 AND 2032(%)
FIGURE 18. COMPARATIVE SHARE ANALYSIS OF ANTIBODY PRODUCTION MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY 2022 AND 2032(%)
FIGURE 19. COMPARATIVE SHARE ANALYSIS OF ANTIBODY PRODUCTION MARKET FOR CROS AND CDMOS, BY COUNTRY 2022 AND 2032(%)
FIGURE 20. COMPARATIVE SHARE ANALYSIS OF ANTIBODY PRODUCTION MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
FIGURE 21. ANTIBODY PRODUCTION MARKET BY REGION, 2022 AND 2032(%)
FIGURE 22. U.S. ANTIBODY PRODUCTION MARKET, 2022-2032 ($MILLION)
FIGURE 23. CANADA ANTIBODY PRODUCTION MARKET, 2022-2032 ($MILLION)
FIGURE 24. MEXICO ANTIBODY PRODUCTION MARKET, 2022-2032 ($MILLION)
FIGURE 25. GERMANY ANTIBODY PRODUCTION MARKET, 2022-2032 ($MILLION)
FIGURE 26. FRANCE ANTIBODY PRODUCTION MARKET, 2022-2032 ($MILLION)
FIGURE 27. UK ANTIBODY PRODUCTION MARKET, 2022-2032 ($MILLION)
FIGURE 28. ITALY ANTIBODY PRODUCTION MARKET, 2022-2032 ($MILLION)
FIGURE 29. SPAIN ANTIBODY PRODUCTION MARKET, 2022-2032 ($MILLION)
FIGURE 30. REST OF EUROPE ANTIBODY PRODUCTION MARKET, 2022-2032 ($MILLION)
FIGURE 31. JAPAN ANTIBODY PRODUCTION MARKET, 2022-2032 ($MILLION)
FIGURE 32. CHINA ANTIBODY PRODUCTION MARKET, 2022-2032 ($MILLION)
FIGURE 33. INDIA ANTIBODY PRODUCTION MARKET, 2022-2032 ($MILLION)
FIGURE 34. AUSTRALIA ANTIBODY PRODUCTION MARKET, 2022-2032 ($MILLION)
FIGURE 35. SOUTH KOREA ANTIBODY PRODUCTION MARKET, 2022-2032 ($MILLION)
FIGURE 36. REST OF ASIA-PACIFIC ANTIBODY PRODUCTION MARKET, 2022-2032 ($MILLION)
FIGURE 37. BRAZIL ANTIBODY PRODUCTION MARKET, 2022-2032 ($MILLION)
FIGURE 38. COLOMBIA ANTIBODY PRODUCTION MARKET, 2022-2032 ($MILLION)
FIGURE 39. ARGENTINA ANTIBODY PRODUCTION MARKET, 2022-2032 ($MILLION)
FIGURE 40. REST OF LA ANTIBODY PRODUCTION MARKET, 2022-2032 ($MILLION)
FIGURE 41. GCC ANTIBODY PRODUCTION MARKET, 2022-2032 ($MILLION)
FIGURE 42. SOUTH AFRICA ANTIBODY PRODUCTION MARKET, 2022-2032 ($MILLION)
FIGURE 43. NORTH AFRICA ANTIBODY PRODUCTION MARKET, 2022-2032 ($MILLION)
FIGURE 44. REST OF MEA ANTIBODY PRODUCTION MARKET, 2022-2032 ($MILLION)
FIGURE 45. TOP WINNING STRATEGIES, BY YEAR
FIGURE 46. TOP WINNING STRATEGIES, BY DEVELOPMENT
FIGURE 47. TOP WINNING STRATEGIES, BY COMPANY
FIGURE 48. PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 49. COMPETITIVE DASHBOARD
FIGURE 50. COMPETITIVE HEATMAP: ANTIBODY PRODUCTION MARKET
FIGURE 51. TOP PLAYER POSITIONING, 2022

Product Code: A03233

The antibody production market was valued at $12.3 billion in 2022 and is projected to reach $29.4 billion by 2032, registering a CAGR of 9.1% from 2023 to 2032. Antibody production refers to the process by which specialized cells in the immune system, called B cells, produce antibodies in response to the presence of foreign substances, such as bacteria, viruses, or other pathogens. Antibodies, also known as immunoglobulins, are Y-shaped proteins that specifically recognize and bind to antigens, which are unique molecules present on the surface of pathogens.

The process of antibody production begins when a B cell encounters an antigen that matches its specific receptor. This encounter triggers the activation and proliferation of the B cell, leading to the production of a large number of identical B cells, known as a clone. These activated B cells then differentiate into plasma cells, which are antibody-producing factories. Plasma cells secrete large quantities of antibodies into the bloodstream and other bodily fluids, where they can bind to and neutralize pathogens or mark them for destruction by other immune cells.

Factors driving the growth of the antibody production market include increase in prevalence of chronic diseases necessitating targeted therapies, advancements in biotechnology enhancing production efficiency and scalability, rising demand for monoclonal antibodies across therapeutic and research applications, and supportive government initiatives fostering research and development in antibody-based therapeutics. In addition, the biopharmaceutical industry is experiencing rapid growth due to increase in investments in research and development, as well as the rise in adoption of biologics-based therapies. Antibodies represent a significant portion of biopharmaceuticals, driving the demand for antibody production technologies and services.

Furthermore, government initiatives aimed at promoting biotechnology research and development, as well as funding support for biopharmaceutical companies and academic institutions, are fostering innovation and growth in the antibody production market. Public-private partnerships and grant programs are also contributing to the expansion of antibody-related research and commercialization efforts. For instance, in 2023, government initiatives for antibody production include the National Institutes of Health (NIH) supporting research to define mechanisms for establishing and maintaining immune responses, such as broadly neutralizing HIV antibodies to protect against HIV acquisition. Thus, rise in government initiatives for research and commercialization of antibodies further propels the market growth. Moreover, monoclonal antibodies (mAbs) have gained widespread acceptance in various therapeutic areas due to their high specificity and efficacy. The increasing number of approved monoclonal antibody drugs and their expanding applications in oncology, immunology, and other fields are driving the demand for antibody production and reagents.

However, the high costs associated with the development and production of antibodies present a significant restraint on the growth of the antibody production market. Antibody development involves a series of complex and resource-intensive processes, including antigen selection, hybridoma or phage display library generation, antibody screening, and optimization. These processes require specialized expertise, sophisticated equipment, and extensive laboratory resources, driving up development costs. Additionally, the production of therapeutic antibodies involves large-scale cell culture, purification, formulation, and quality control steps, all of which contribute to high production costs which may restrain market growth. On the other hand, the growing biopharmaceutical industry, coupled with increase in investments in research and development, presents opportunity to market growth.

The antibody production market is segmented on the basis of product, process, end user and region. By product, the market is bifurcated into instruments and consumables. The instruments segment is further categorized into bioreactors, chromatography systems, and filtration systems. By process, the market is divided into upstream processing and downstream processing. As per end user, it is segregated into pharmaceutical and biotechnology companies, CROs and CDMOs, and others.

Region-wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), LA (Brazil, Colombia, Argentina, and rest of LA), and MEA (GCC, South Africa, North Africa, and rest of MEA). Major key players that operate in the antibody production market are Thermo Fisher Scientific Inc., Sartorius AG, Cellabcdmo, Agilent, Genetix Biotech Asia Pvt. Ltd., Cell Culture Company, Bio-Rad Laboratories, Inc, TECNIC, Merck KGaA, and Danaher Corporation. Key players have adopted acquisition as key developmental strategies to improve the product portfolio of the antibody production market.

Key Benefits for Stakeholders

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the antibody production market analysis from 2022 to 2032 to identify the prevailing antibody production market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the antibody production market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global antibody production market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

Quarterly Update and* (only available with a corporate license, on listed price)
5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
Free Upcoming Version on the Purchase of Five and Enterprise User License.
16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
Free data Pack on the Five and Enterprise User License. (Excel version of the report)
Free Updated report if the report is 6-12 months old or older.
24-hour priority response*
Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

Regulatory Guidelines
Additional company profiles with specific to client's interest
Additional country or region analysis- market size and forecast
Expanded list for Company Profiles
Historic market data
Key player details (including location, contact details, supplier/vendor network etc. in excel format)

Key Market Segments

By End User

Pharmaceutical and Biotechnology Companies
CROs and CDMOs
Others

By Product

Instruments
- Type
- Bioreactors
- Chromatography Systems
- Filtration Systems
Consumables

By Process

Upstream Processing
Downstream Processing

By Region

North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Colombia
- Argentina
- Rest Of La
Middle East and Africa
- Gcc
- South Africa
- North Africa
- Rest Of Mea

Key Market Players:

Thermo Fisher Scientific Inc.
Sartorius AG
Cellabcdmo
Agilent Technologies, Inc.
Genetix Biotech Asia Pvt. Ltd.
Cell Culture Company
Bio-Rad Laboratories, Inc.
TECNIC
Merck KGaA
Danaher Corporation

CHAPTER 1: INTRODUCTION

1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research methodology
- 1.4.1. Primary research
- 1.4.2. Secondary research
- 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. CXO perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Key findings
- 3.2.1. Top impacting factors
- 3.2.2. Top investment pockets
3.3. Porter's five forces analysis
3.4. Market dynamics
- 3.4.1. Drivers
- 3.4.2. Restraints
- 3.4.3. Opportunities

CHAPTER 4: ANTIBODY PRODUCTION MARKET, BY PRODUCT

4.1. Overview
- 4.1.1. Market size and forecast
4.2. Instruments
- 4.2.1. Key market trends, growth factors and opportunities
- 4.2.2. Market size and forecast, by region
- 4.2.3. Market share analysis by country
- 4.2.4. Instruments Antibody Production Market by Type
4.3. Consumables
- 4.3.1. Key market trends, growth factors and opportunities
- 4.3.2. Market size and forecast, by region
- 4.3.3. Market share analysis by country

CHAPTER 5: ANTIBODY PRODUCTION MARKET, BY PROCESS

5.1. Overview
- 5.1.1. Market size and forecast
5.2. Upstream Processing
- 5.2.1. Key market trends, growth factors and opportunities
- 5.2.2. Market size and forecast, by region
- 5.2.3. Market share analysis by country
5.3. Downstream Processing
- 5.3.1. Key market trends, growth factors and opportunities
- 5.3.2. Market size and forecast, by region
- 5.3.3. Market share analysis by country

CHAPTER 6: ANTIBODY PRODUCTION MARKET, BY END USER

6.1. Overview
- 6.1.1. Market size and forecast
6.2. Pharmaceutical and Biotechnology Companies
- 6.2.1. Key market trends, growth factors and opportunities
- 6.2.2. Market size and forecast, by region
- 6.2.3. Market share analysis by country
6.3. CROs and CDMOs
- 6.3.1. Key market trends, growth factors and opportunities
- 6.3.2. Market size and forecast, by region
- 6.3.3. Market share analysis by country
6.4. Others
- 6.4.1. Key market trends, growth factors and opportunities
- 6.4.2. Market size and forecast, by region
- 6.4.3. Market share analysis by country

CHAPTER 7: ANTIBODY PRODUCTION MARKET, BY REGION

7.1. Overview
- 7.1.1. Market size and forecast By Region
7.2. North America
- 7.2.1. Key market trends, growth factors and opportunities
- 7.2.2. Market size and forecast, by Product
- 7.2.3. Market size and forecast, by Process
- 7.2.4. Market size and forecast, by End User
- 7.2.5. Market size and forecast, by country
  - 7.2.5.1. U.S.
  - 7.2.5.1.1. Market size and forecast, by Product
  - 7.2.5.1.2. Market size and forecast, by Process
  - 7.2.5.1.3. Market size and forecast, by End User
  - 7.2.5.2. Canada
  - 7.2.5.2.1. Market size and forecast, by Product
  - 7.2.5.2.2. Market size and forecast, by Process
  - 7.2.5.2.3. Market size and forecast, by End User
  - 7.2.5.3. Mexico
  - 7.2.5.3.1. Market size and forecast, by Product
  - 7.2.5.3.2. Market size and forecast, by Process
  - 7.2.5.3.3. Market size and forecast, by End User
7.3. Europe
- 7.3.1. Key market trends, growth factors and opportunities
- 7.3.2. Market size and forecast, by Product
- 7.3.3. Market size and forecast, by Process
- 7.3.4. Market size and forecast, by End User
- 7.3.5. Market size and forecast, by country
  - 7.3.5.1. Germany
  - 7.3.5.1.1. Market size and forecast, by Product
  - 7.3.5.1.2. Market size and forecast, by Process
  - 7.3.5.1.3. Market size and forecast, by End User
  - 7.3.5.2. France
  - 7.3.5.2.1. Market size and forecast, by Product
  - 7.3.5.2.2. Market size and forecast, by Process
  - 7.3.5.2.3. Market size and forecast, by End User
  - 7.3.5.3. UK
  - 7.3.5.3.1. Market size and forecast, by Product
  - 7.3.5.3.2. Market size and forecast, by Process
  - 7.3.5.3.3. Market size and forecast, by End User
  - 7.3.5.4. Italy
  - 7.3.5.4.1. Market size and forecast, by Product
  - 7.3.5.4.2. Market size and forecast, by Process
  - 7.3.5.4.3. Market size and forecast, by End User
  - 7.3.5.5. Spain
  - 7.3.5.5.1. Market size and forecast, by Product
  - 7.3.5.5.2. Market size and forecast, by Process
  - 7.3.5.5.3. Market size and forecast, by End User
  - 7.3.5.6. Rest of Europe
  - 7.3.5.6.1. Market size and forecast, by Product
  - 7.3.5.6.2. Market size and forecast, by Process
  - 7.3.5.6.3. Market size and forecast, by End User
7.4. Asia-Pacific
- 7.4.1. Key market trends, growth factors and opportunities
- 7.4.2. Market size and forecast, by Product
- 7.4.3. Market size and forecast, by Process
- 7.4.4. Market size and forecast, by End User
- 7.4.5. Market size and forecast, by country
  - 7.4.5.1. Japan
  - 7.4.5.1.1. Market size and forecast, by Product
  - 7.4.5.1.2. Market size and forecast, by Process
  - 7.4.5.1.3. Market size and forecast, by End User
  - 7.4.5.2. China
  - 7.4.5.2.1. Market size and forecast, by Product
  - 7.4.5.2.2. Market size and forecast, by Process
  - 7.4.5.2.3. Market size and forecast, by End User
  - 7.4.5.3. India
  - 7.4.5.3.1. Market size and forecast, by Product
  - 7.4.5.3.2. Market size and forecast, by Process
  - 7.4.5.3.3. Market size and forecast, by End User
  - 7.4.5.4. Australia
  - 7.4.5.4.1. Market size and forecast, by Product
  - 7.4.5.4.2. Market size and forecast, by Process
  - 7.4.5.4.3. Market size and forecast, by End User
  - 7.4.5.5. South Korea
  - 7.4.5.5.1. Market size and forecast, by Product
  - 7.4.5.5.2. Market size and forecast, by Process
  - 7.4.5.5.3. Market size and forecast, by End User
  - 7.4.5.6. Rest of Asia-Pacific
  - 7.4.5.6.1. Market size and forecast, by Product
  - 7.4.5.6.2. Market size and forecast, by Process
  - 7.4.5.6.3. Market size and forecast, by End User
7.5. Latin America
- 7.5.1. Key market trends, growth factors and opportunities
- 7.5.2. Market size and forecast, by Product
- 7.5.3. Market size and forecast, by Process
- 7.5.4. Market size and forecast, by End User
- 7.5.5. Market size and forecast, by country
  - 7.5.5.1. Brazil
  - 7.5.5.1.1. Market size and forecast, by Product
  - 7.5.5.1.2. Market size and forecast, by Process
  - 7.5.5.1.3. Market size and forecast, by End User
  - 7.5.5.2. Colombia
  - 7.5.5.2.1. Market size and forecast, by Product
  - 7.5.5.2.2. Market size and forecast, by Process
  - 7.5.5.2.3. Market size and forecast, by End User
  - 7.5.5.3. Argentina
  - 7.5.5.3.1. Market size and forecast, by Product
  - 7.5.5.3.2. Market size and forecast, by Process
  - 7.5.5.3.3. Market size and forecast, by End User
  - 7.5.5.4. Rest Of La
  - 7.5.5.4.1. Market size and forecast, by Product
  - 7.5.5.4.2. Market size and forecast, by Process
  - 7.5.5.4.3. Market size and forecast, by End User
7.6. Middle East and Africa
- 7.6.1. Key market trends, growth factors and opportunities
- 7.6.2. Market size and forecast, by Product
- 7.6.3. Market size and forecast, by Process
- 7.6.4. Market size and forecast, by End User
- 7.6.5. Market size and forecast, by country
  - 7.6.5.1. Gcc
  - 7.6.5.1.1. Market size and forecast, by Product
  - 7.6.5.1.2. Market size and forecast, by Process
  - 7.6.5.1.3. Market size and forecast, by End User
  - 7.6.5.2. South Africa
  - 7.6.5.2.1. Market size and forecast, by Product
  - 7.6.5.2.2. Market size and forecast, by Process
  - 7.6.5.2.3. Market size and forecast, by End User
  - 7.6.5.3. North Africa
  - 7.6.5.3.1. Market size and forecast, by Product
  - 7.6.5.3.2. Market size and forecast, by Process
  - 7.6.5.3.3. Market size and forecast, by End User
  - 7.6.5.4. Rest Of Mea
  - 7.6.5.4.1. Market size and forecast, by Product
  - 7.6.5.4.2. Market size and forecast, by Process
  - 7.6.5.4.3. Market size and forecast, by End User

CHAPTER 8: COMPETITIVE LANDSCAPE

8.1. Introduction
8.2. Top winning strategies
8.3. Product mapping of top 10 player
8.4. Competitive dashboard
8.5. Competitive heatmap
8.6. Top player positioning, 2022

CHAPTER 9: COMPANY PROFILES

9.1. Thermo Fisher Scientific Inc.
- 9.1.1. Company overview
- 9.1.2. Key executives
- 9.1.3. Company snapshot
- 9.1.4. Operating business segments
- 9.1.5. Product portfolio
- 9.1.6. Business performance
- 9.1.7. Key strategic moves and developments
9.2. Sartorius AG
- 9.2.1. Company overview
- 9.2.2. Key executives
- 9.2.3. Company snapshot
- 9.2.4. Operating business segments
- 9.2.5. Product portfolio
- 9.2.6. Business performance
- 9.2.7. Key strategic moves and developments
9.3. Cellabcdmo
- 9.3.1. Company overview
- 9.3.2. Key executives
- 9.3.3. Company snapshot
- 9.3.4. Operating business segments
- 9.3.5. Product portfolio
- 9.3.6. Business performance
- 9.3.7. Key strategic moves and developments
9.4. Agilent Technologies, Inc.
- 9.4.1. Company overview
- 9.4.2. Key executives
- 9.4.3. Company snapshot
- 9.4.4. Operating business segments
- 9.4.5. Product portfolio
- 9.4.6. Business performance
- 9.4.7. Key strategic moves and developments
9.5. Genetix Biotech Asia Pvt. Ltd.
- 9.5.1. Company overview
- 9.5.2. Key executives
- 9.5.3. Company snapshot
- 9.5.4. Operating business segments
- 9.5.5. Product portfolio
- 9.5.6. Business performance
- 9.5.7. Key strategic moves and developments
9.6. Cell Culture Company
- 9.6.1. Company overview
- 9.6.2. Key executives
- 9.6.3. Company snapshot
- 9.6.4. Operating business segments
- 9.6.5. Product portfolio
- 9.6.6. Business performance
- 9.6.7. Key strategic moves and developments
9.7. Bio-Rad Laboratories, Inc.
- 9.7.1. Company overview
- 9.7.2. Key executives
- 9.7.3. Company snapshot
- 9.7.4. Operating business segments
- 9.7.5. Product portfolio
- 9.7.6. Business performance
- 9.7.7. Key strategic moves and developments
9.8. TECNIC
- 9.8.1. Company overview
- 9.8.2. Key executives
- 9.8.3. Company snapshot
- 9.8.4. Operating business segments
- 9.8.5. Product portfolio
- 9.8.6. Business performance
- 9.8.7. Key strategic moves and developments
9.9. Merck KGaA
- 9.9.1. Company overview
- 9.9.2. Key executives
- 9.9.3. Company snapshot
- 9.9.4. Operating business segments
- 9.9.5. Product portfolio
- 9.9.6. Business performance
- 9.9.7. Key strategic moves and developments
9.10. Danaher Corporation
- 9.10.1. Company overview
- 9.10.2. Key executives
- 9.10.3. Company snapshot
- 9.10.4. Operating business segments
- 9.10.5. Product portfolio
- 9.10.6. Business performance
- 9.10.7. Key strategic moves and developments

抗体生産市場：製品別、工程別、エンドユーザー別：世界の機会分析と産業予測、2023～2032年

Antibody Production Market By Product, By Process, By End User : Global Opportunity Analysis and Industry Forecast, 2023-2032

目次

第1章イントロダクション

第2章エグゼクティブサマリー

第3章市場概要

第4章抗体生産市場：製品別

第5章抗体製造市場：工程別

第6章抗体製造市場：エンドユーザー別

第7章アンチボディ製造市場抗体製造市場：地域別

第8章競争情勢

第9章企業プロファイル

LIST OF TABLES

LIST OF FIGURES

Key Market Segments

By End User

By Product

By Process

By Region

Key Market Players:

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

CHAPTER 2: EXECUTIVE SUMMARY

CHAPTER 3: MARKET OVERVIEW

CHAPTER 4: ANTIBODY PRODUCTION MARKET, BY PRODUCT

CHAPTER 5: ANTIBODY PRODUCTION MARKET, BY PROCESS

CHAPTER 6: ANTIBODY PRODUCTION MARKET, BY END USER

CHAPTER 7: ANTIBODY PRODUCTION MARKET, BY REGION

CHAPTER 8: COMPETITIVE LANDSCAPE

CHAPTER 9: COMPANY PROFILES

抗体生産市場：製品別、工程別、エンドユーザー別：世界の機会分析と産業予測、2023～2032年

Antibody Production Market By Product, By Process, By End User : Global Opportunity Analysis and Industry Forecast, 2023-2032

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場概要

第4章 抗体生産市場：製品別

第5章 抗体製造市場：工程別

第6章 抗体製造市場：エンドユーザー別

第7章 アンチボディ製造市場抗体製造市場：地域別

第8章 競争情勢

第9章 企業プロファイル

LIST OF TABLES

LIST OF FIGURES

Key Market Segments

By End User

By Product

By Process

By Region

Key Market Players:

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

CHAPTER 2: EXECUTIVE SUMMARY

CHAPTER 3: MARKET OVERVIEW

CHAPTER 4: ANTIBODY PRODUCTION MARKET, BY PRODUCT

CHAPTER 5: ANTIBODY PRODUCTION MARKET, BY PROCESS

CHAPTER 6: ANTIBODY PRODUCTION MARKET, BY END USER

CHAPTER 7: ANTIBODY PRODUCTION MARKET, BY REGION

CHAPTER 8: COMPETITIVE LANDSCAPE

CHAPTER 9: COMPANY PROFILES

第1章イントロダクション

第2章エグゼクティブサマリー

第3章市場概要

第4章抗体生産市場：製品別

第5章抗体製造市場：工程別

第6章抗体製造市場：エンドユーザー別

第7章アンチボディ製造市場抗体製造市場：地域別

第8章競争情勢

第9章企業プロファイル